drugset / Trial / NCT00913419

To Demonstrate the Relative Bioavailability of Cyclobenzaprine HCl Tablets

NCT00913419 ↗

Phase 1 Completed 30 enrolled Sandoz
RandomizedCrossoverOpen-labelTreatment

Summary

To demonstrate the relative bioavailability of Cyclobenzaprine HCl tablets.

Timeline

Start
1988-11
Primary completion
1988-12
Completion
1988-12

Drugs

EvaluationDrugModalityDoseRoute
Subject cyclobenzaprine Unknown 10 mg —

Indications